Clinical Trials Logo
  1. Home
  2. Glioblastoma, IDH-wildtype
  3. NCT06095375

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients — REGOMA-2  

Glioblastoma, IDH-wildtype Clinical Trial

Official title:
Regorafenib in Combination With Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed MGMT-Methylated, IDH Wild-type Glioblastoma. A Phase I Dose-finding Study

Clinical Trial Summary

This study will evaluate the addition of regorafenib to standard of care treatment with TMZ as adjuvant therapy, and in combination with TMZ+RT as concomitant therapy. The standard of care for newly diagnosed GBM (ndGBM) includes surgical resection to the extent that is safely feasible, followed by RT plus concomitant TMZ chemotherapy, and up to 6 months of adjuvant TMZ. The dose escalation will be explored following a "3+3" design, escalating oral doses of regorafenib in combination with adjuvant (maintenance) TMZ (cohort A) to estimate the MTD of regorafenib as adjuvant (maintenance) therapy. After finding the MTD in the Adjuvant Therapy dose escalation, the Concomitant Therapy (cohort B) dose escalation will start, exploring escalating oral doses of regorafenib in combination with concomitant TMZ+RT, to estimate the MTD of regorafenib as concomitant therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06095375
Study type Interventional
Source Istituto Oncologico Veneto IRCCS
Contact Gian Luca De Salvo, MD
Phone 00390498215704
Email clinical.trial@iov.veneto.it
Status Recruiting
Phase Phase 1
Start date July 4, 2022
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05941234 - Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma N/A
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT06160596 - Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Recruiting NCT06047379 - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Phase 1/Phase 2
Not yet recruiting NCT05842746 - Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma Phase 2
Not yet recruiting NCT04945148 - Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide Phase 2
Active, not recruiting NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Recruiting NCT05326334 - THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)
Recruiting NCT05375318 - BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
Not yet recruiting NCT06359379 - Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter Phase 2
Recruiting NCT05879367 - Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT05759195 - Biomolecular Analysis for Predicting Response to Regorafenib N/A
Recruiting NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Recruiting NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Recruiting NCT06273176 - The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Recruiting NCT06146738 - The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Recruiting NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Not yet recruiting NCT05879250 - WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Suspended NCT04145115 - A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden Phase 2
Recruiting NCT04197934 - WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases Phase 1